CDDO-TFEA
Product Specifications
Product Name Alternative
CDDO-Trifluoethyl amide; RTA 404; TP-500
UNSPSC Description
CDDO-TFEA (RTA 404; TP-500) is a trifluoroacetamide derivative of CDDO with enhanced ability to cross the blood-brain barrier. CDDO is an Nrf2 activator that inhibits proliferation and induces differentiation and apoptosis in various cancer cells. CDDO-TFEA can enhance Nrf2 expression and signaling in various neurodegenerative disease models, including those mimicking multiple sclerosis, amyotrophic lateral sclerosis, and Huntington's disease. CDDO-TFEA induces apoptosis and blocks colony formation in Ewing's sarcoma and neuroblastoma cell lines with IC50 values ranging from 85-170 nM.
Target Antigen
Apoptosis; Keap1-Nrf2
Type
Reference compound
Related Pathways
Apoptosis;NF-κB
Field of Research
cancer
Assay Protocol
https://www.medchemexpress.com/cddo-tfea.html
Smiles
CC(C)([C@](CC[C@@]([C@@]1(CC[C@]2(CCC(C)(C[C@]2([C@]13[H])[H])C)C(NCC(F)(F)F)=O)C)4C)5[H])C(C(C#N)=C[C@]5(C)C4=CC3=O)=O
Molecular Weight
572.70
References & Citations
[1]Stack, et al. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington’s disease. Free Radic. Biol. Med. 49(2), 147-158 (2010).
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-130495/CDDO-TFEA-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-130495/
Clinical Information
No Development Reported
CAS Number
932730-52-4
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items